Online citations, reference lists, and bibliographies.
← Back to Search

Bortezomib (Velcade): A First‐in‐Class Proteasome Inhibitor

Ben S Greener, David S. Millan
Published 2010 · Chemistry

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
This paper references
10.1021/JA01547A033
Aryl Boronic Acids. II. Aryl Boronic Anhydrides and their Amine Complexes1
H. Snyder (1958)
10.1021/JA00545A045
.alpha.-Chloro boronic esters from homologation of boronic esters
D. Matteson (1980)
10.1021/JA00545A046
Directed chiral synthesis with pinanediol boronic esters
D. Matteson (1980)
10.1021/JA00407A051
R-1-Acetamido-2-phenylethaneboronic acid. A specific transition-state analog for chymotrypsin
D. Matteson (1981)
10.1021/OM50004A008
Organoboranes. 30. Convenient procedures for the synthesis of alkyl- and alkenylboronic acids and esters
H. Brown (1983)
10.1021/OM50003A004
Epimerization of .alpha.-chloroboronic esters by lithium and zinc chlorides
D. Matteson (1983)
10.1016/S0040-4039(00)99616-3
New coupling reagents in peptide chemistry
R. Knorr (1989)
10.1006/BBRC.1993.2378
Purification and characterization of a Z-Leu-Leu-Leu-MCA degrading protease expected to regulate neurite formation: a novel catalytic activity in proteasome.
S. Tsubuki (1993)
10.1073/PNAS.94.13.6629
Covalent modification of the active site threonine of proteasomal beta subunits and the Escherichia coli homolog HslV by a new class of inhibitors.
M. Bogyo (1997)
10.1016/S0960-894X(98)00029-8
Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids.
J. Adams (1998)
Proteasome inhibitors: a novel class of potent and effective antitumor agents.
J. Adams (1999)
10.1358/DOF.2002.027.11.697067
Bortezomib, a proteasome inhibitor, in cancer therapy: from concept to clinic
J. Albanell (2002)
Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model.
Richard A. Leblanc (2002)
10.1016/S1535-6108(04)00120-5
The development of proteasome inhibitors as anticancer drugs.
J. Adams (2004)
10.1517/14656566.5.6.1321
A review of the proteasome inhibitor bortezomib in multiple myeloma
P. Richardson (2004)
10.1146/ANNUREV.PHARMTOX.46.120604.141300
The proteasome and proteasome inhibitors in cancer therapy.
P. Voorhees (2006)
10.1517/14656566.7.10.1337
Bortezomib for multiple myeloma
R. Popat (2006)
10.1182/BLOOD-2007-01-065888
Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma.
D. Kuhn (2007)
10.1021/ja800829y
Asymmetric copper-catalyzed synthesis of alpha-amino boronate esters from N-tert-butanesulfinyl aldimines.
M. A. Beenen (2008)
10.1021/jm7010589
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
Bruce D. Dorsey (2008)
10.1517/13543780903002074
Clinical development of novel proteasome inhibitors for cancer treatment
H. Yang (2009)
10.1158/1535-7163.MCT-09-0239
The relationship among tumor architecture, pharmacokinetics, pharmacodynamics, and efficacy of bortezomib in mouse xenograft models
M. Williamson (2009)
10.2174/092986709787581860
Proteasome regulators: activators and inhibitors.
L. Huang (2009)
10.1016/J.TET.2009.06.042
A convergent approach to synthesis of bortezomib: the use of TBTU suppresses racemization in the fragment condensation
A. S. Ivanov (2009)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar